Press release content from PR Newswire. The AP news staff was not involved in its creation.
New Treatment for Severe Emphysema Now Covered Under Highmark Blue Cross Blue Shield
January 18, 2021 GMT
The FDA-Approved Olympus Spiration® Valve System Is a Breakthrough Device Used for the Therapeutic Treatment of Severe Emphysema, a Form of COPD.
The FDA-Approved Olympus Spiration® Valve System Is a Breakthrough Device Used for the Therapeutic Treatment of Severe Emphysema, a Form of COPD.
CENTER VALLEY, Pa., Jan. 18, 2021 /PRNewswire/ Olympus announced that Highmark Blue Cross Blue Shield (BCBS) updated its coverage policy to include the Spiration® Valve System for eligible patients suffering from severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). This coverage provides a minimally invasive treatment alternative for eligible patients.
DENVER A study in the
Journal of Thoracic Oncology (JTO) comparing surgeries performed at one Chinese hospital in 2019 with a similar date range during the COVID-19 pandemic found that routine thoracic surgery and invasive examinations were performed safely. The
JTO is the official journal of the International Association for the Study of Lung Cancer.
Wentao Fang, MD, chief director of the Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China and his colleagues analyzed the number of elective procedures by a single surgeon team between 2019 and 2020 and compared the clinicopathological characteristics, surgical procedures and perioperative results of this year with the corresponding period last year.
Share this article
Share this article has undergone multiple quantitative tests that demonstrate its filtration system effectively blocks passage of aerosolized viral particles such as SARS-CoV-2, the virus responsible for COVID-19. This would effectively mitigate cross-contamination and transmission of infectious aerosols. The filtration found in Thopaz+ can help provide a safeguard for patients and staff.
(PRNewsfoto/Medela LLC) We understand the critical need for a solution like Thopaz+ that can help healthcare professionals provide safer cardiothoracic drainage and reduce cross contamination as well as healthcare-associated infections (HAI), during the COVID-19 pandemic and beyond, said Melissa Gonzales, RN, BSN, executive vice president of Medela Americas. With its intuitive, easy-to-use design and filtration capabilities, Thopaz+ was developed to meet the evolving needs of healthcare professionals and patients, simplify use while improving health outcomes and reduce co